| Entry |
|
|---|
| Name |
Fomepizole (JAN/USAN/INN);
Antizol (TN) |
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C4H6N2
|
|---|
| Exact mass |
82.0531
|
|---|
| Mol weight |
82.10
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
|
|---|
| Remark |
| Therapeutic category: | 3929 |
|
|---|
| Efficacy |
Antidote (ethyleneglycol, methanol), Alcohol dehydrogenase inhibitor |
|---|
| Target |
|
|---|
| Pathway |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450 |
|
|---|
| Interaction |
CYP inhibition: CYP2D6 [HSA: 1565], CYP2E1 [HSA: 1571], CYP1A2 [HSA: 1544], CYP2A6 [HSA: 1548], CYP2C9 [HSA: 1559], CYP3A4 [HSA: 1576]
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
V VARIOUS
V03 ALL OTHER THERAPEUTIC PRODUCTS
V03A ALL OTHER THERAPEUTIC PRODUCTS
V03AB Antidotes
V03AB34 Fomepizole
D00707 Fomepizole (JAN/USAN/INN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
392 Antidotes
3929 Others
D00707 Fomepizole (JAN/USAN/INN)
Drug groups [BR:br08330]
Metabolizing enzyme inhibitor
DG01634 CYP1A2 inhibitor
D00707 Fomepizole
DG01525 CYP2A6 inhibitor
D00707 Fomepizole
DG01643 CYP2C9 inhibitor
D00707 Fomepizole
DG01645 CYP2D6 inhibitor
D00707 Fomepizole
DG02884 CYP2E1 inhibitor
D00707 Fomepizole
DG02852 CYP3A/CYP3A4 inhibitor
DG01522 CYP3A4 inhibitor
D00707 Fomepizole
Target-based classification of drugs [BR:br08310]
Enzymes
Oxidoreductases (EC1)
Dehydrogenases
ADH
D00707 Fomepizole (JAN/USAN/INN) <JP/US>
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D00707
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00707
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 6
1 C8y C 21.8459 -16.2459
2 C8x C 23.2400 -16.2459
3 C8x C 21.4084 -14.9216
4 C1a C 20.8425 -17.2317
5 N5x N 23.6775 -14.9216
6 N4x N 22.5459 -14.0931
BOND 6
1 1 2 1
2 1 3 2
3 1 4 1
4 2 5 2
5 3 6 1
6 5 6 1
|
|---|
